Compare Stocks: ABP, XTLB, AQB, and LIMN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABP Abpro	$0.52	$0.52	$0.52 ▼ $29.97	$1.42M	N/A	5.06 million shs	N/A
AQB AquaBounty Technologies	$0.88 -15.3%	$1.14	$0.77 ▼ $2.95	$5.61M	1.45	49,952 shs	670,938 shs
LIMN Liminatus Pharma	$4.18 +3.7%	$4.84	$3.29 ▼ $141.50	$5.47M	5.3	31,408 shs	16,849 shs
XTLB XTL Biopharmaceuticals	$2.41 +9.5%	$2.66	$2.01 ▼ $10.28	$5.63M	1.38	4,279 shs	13,107 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABP Abpro	0.00%	0.00%	0.00%	0.00%	-92.32%
AQB AquaBounty Technologies	-15.26%	-22.01%	-33.74%	-19.88%	-47.85%
LIMN Liminatus Pharma	+3.72%	+23.30%	-9.33%	-20.91%	-94.15%
XTLB XTL Biopharmaceuticals	+6.17%	-0.62%	-7.31%	+2.12%	-87.07%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABP Abpro	$0.52	$0.52	$0.52 ▼ $29.97	$1.42M	N/A	5.06 million shs	N/A
AQB AquaBounty Technologies	$0.88 -15.3%	$1.14	$0.77 ▼ $2.95	$5.61M	1.45	49,952 shs	670,938 shs
LIMN Liminatus Pharma	$4.18 +3.7%	$4.84	$3.29 ▼ $141.50	$5.47M	5.3	31,408 shs	16,849 shs
XTLB XTL Biopharmaceuticals	$2.41 +9.5%	$2.66	$2.01 ▼ $10.28	$5.63M	1.38	4,279 shs	13,107 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABP Abpro	0.00%	0.00%	0.00%	0.00%	-92.32%
AQB AquaBounty Technologies	-15.26%	-22.01%	-33.74%	-19.88%	-47.85%
LIMN Liminatus Pharma	+3.72%	+23.30%	-9.33%	-20.91%	-94.15%
XTLB XTL Biopharmaceuticals	+6.17%	-0.62%	-7.31%	+2.12%	-87.07%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABP Abpro	1.50	Reduce	N/A	N/A
AQB AquaBounty Technologies	1.00	Sell	N/A	N/A
LIMN Liminatus Pharma	1.00	Sell	N/A	N/A
XTLB XTL Biopharmaceuticals	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest ABP, XTLB, AQB, and LIMN Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/14/2026	AQB AquaBounty Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/3/2026	LIMN Liminatus Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/28/2026	AQB AquaBounty Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/20/2026	LIMN Liminatus Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/12/2026	AQB AquaBounty Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/8/2026	AQB AquaBounty Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/6/2026	XTLB XTL Biopharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABP Abpro	N/A	N/A	N/A	N/A	($8.83) per share	N/A
AQB AquaBounty Technologies	$2.47M	1.84	N/A	N/A	($0.49) per share	-1.80
LIMN Liminatus Pharma	N/A	N/A	N/A	N/A	($18.13) per share	N/A
XTLB XTL Biopharmaceuticals	$450K	12.69	N/A	N/A	($0.11) per share	-21.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABP Abpro	-$7.23M	-$4.23	N/A	N/A	N/A	N/A	N/A	-344.76%	N/A
AQB AquaBounty Technologies	-$18.49M	-$0.82	N/A	N/A	N/A	N/A	-147.07%	-28.73%	11/10/2026 (Estimated)
LIMN Liminatus Pharma	-$10.21M	-$23.50	N/A	N/A	N/A	N/A	N/A	-256.58%	N/A
XTLB XTL Biopharmaceuticals	-$6.97M	-$0.64	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest ABP, XTLB, AQB, and LIMN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	LIMN Liminatus Pharma	N/A	-$1.50	N/A	-$0.03	N/A	N/A
8/6/2026	Q2 2026	AQB AquaBounty Technologies	N/A	-$0.26	N/A	-$0.32	N/A	N/A
6/30/2026	Q4 2025	XTLB XTL Biopharmaceuticals	N/A	-$0.10	N/A	-$0.10	N/A	($0.26) million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABP Abpro	N/A	N/A	N/A	N/A	N/A
AQB AquaBounty Technologies	N/A	N/A	N/A	N/A	N/A
LIMN Liminatus Pharma	N/A	N/A	N/A	N/A	N/A
XTLB XTL Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABP Abpro	N/A	0.07	0.07
AQB AquaBounty Technologies	N/A	4.26	4.26
LIMN Liminatus Pharma	N/A	1.12	1.12
XTLB XTL Biopharmaceuticals	N/A	0.40	0.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABP Abpro	23.30%
AQB AquaBounty Technologies	8.92%
LIMN Liminatus Pharma	N/A
XTLB XTL Biopharmaceuticals	4.40%

Insider Ownership

Company	Insider Ownership
ABP Abpro	13.70%
AQB AquaBounty Technologies	1.02%
LIMN Liminatus Pharma	19.40%
XTLB XTL Biopharmaceuticals	29.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABP Abpro	15	2.72 million	2.34 million	N/A
AQB AquaBounty Technologies	100	5.15 million	5.10 million	No Data
LIMN Liminatus Pharma	1	1.34 million	1.08 million	N/A
XTLB XTL Biopharmaceuticals	10	2.37 million	1.68 million	Not Optionable

ABP, XTLB, AQB, and LIMN Headlines

Recent News About These Companies

XTL Biopharmaceuticals Ltd. Sponsored ADR

July 8, 2026 | cnn.com

XTL Biopharmaceuticals Ltd. American Depositary Shares (XTLB) After-Hours

July 1, 2026 | nasdaq.com

XTL Biopharmaceuticals Completes Acquisition of Psyga Bio to Establish Psychedelic Biotechnology Platform

June 30, 2026 | quiverquant.comQ

XTL Completed the Acquisition of Psyga Bio Ltd.

June 30, 2026 | globenewswire.com

XTL Biopharmaceuticals Adjourns Extraordinary Shareholder Meeting to June 29, 2026

June 23, 2026 | tipranks.com

XTL Biopharmaceuticals Ltd.: XTL Announces Receipt of Staff Delist Determination from Nasdaq

May 23, 2026 | finanznachrichten.de

XTL Announces Receipt of Staff Delist Determination from Nasdaq

May 22, 2026 | globenewswire.com

XTL Biopharmaceuticals Calls June 22, 2026 Meeting to Approve Psyga Bio Acquisition and Capital Raise

May 15, 2026 | tipranks.com

XTL Biopharmaceuticals Ltd ADR XTLB

May 14, 2026 | morningstar.comM

XTL Biopharmaceuticals Delays 20-F Amid Subsidiary Liquidation

May 3, 2026 | theglobeandmail.com

XTL Biopharmaceuticals Ltd.

May 1, 2026 | marketwatch.com

Washington Just Opened the Door to Psychedelic Medicine; This Microcap Already Has a Key

May 1, 2026 | theglobeandmail.com

XTLB stock surges 50%, breaches 200-DMA for first time in over 3 months – here’s what the acquisition of Psyga Bio brings to the table

May 1, 2026 | msn.com

XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and ...

April 29, 2026 | markets.businessinsider.com

XTL Biopharmaceuticals (XTLB) acquisition of Psyga Bio targets psychedelic biotech growth

April 29, 2026 | msn.com

XTL Biopharmaceuticals soars after all-stock Psyga Bio acquisition announcement

April 29, 2026 | quiverquant.comQ

XTL Biopharmaceuticals to Acquire PsygaBio in All-Stock Deal to Expand Psychedelic Drug Pipeline

April 29, 2026 | tipranks.com

XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies

April 29, 2026 | globenewswire.com

XTL Biopharmaceuticals Ltd.: XTL Biopharmaceuticals Announces ADS Ratio Change

March 21, 2026 | finanznachrichten.de

XTL Biopharmaceuticals Announces ADS Ratio Change

March 20, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABP, XTLB, AQB, and LIMN Company Descriptions

Abpro NASDAQ:ABP

$0.52 0.00 (0.00%)

As of 09/23/2026

Abpro Holdings Inc. is a biotechnology company. The company's mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.

AquaBounty Technologies NASDAQ:AQB

$0.88 -0.16 (-15.26%)

As of 09/24/2026 04:00 PM Eastern

AquaBounty Technologies, Inc., a biotechnology company, operates in the aquaculture industry in the United States and Canada. The company engages in genetic, genomic, and fish health and nutrition research activities. It also operates salmon farms using proprietary technology. In addition, the company offers AquAdvantage Salmon, a genetically engineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts. The company was formerly known as Aqua Bounty Farms, Inc. and changed its name to AquaBounty Technologies, Inc. in June 2004. AquaBounty Technologies, Inc. was incorporated in 1991 and is headquartered in Harvard, Massachusetts.

Liminatus Pharma NASDAQ:LIMN

$4.18 +0.15 (+3.72%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$4.06 -0.12 (-2.87%)

As of 09/24/2026 07:55 PM Eastern

Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.

XTL Biopharmaceuticals NASDAQ:XTLB

$2.41 +0.21 (+9.55%)

Closing price 09/24/2026 03:50 PM Eastern

Extended Trading

$2.48 +0.07 (+2.95%)

As of 09/24/2026 07:30 PM Eastern

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABP, XTLB, AQB, and LIMN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABP, XTLB, AQB, and LIMN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABP, XTLB, AQB, and LIMN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABP, XTLB, AQB, and LIMN Company Descriptions

Abpro NASDAQ:ABP

AquaBounty Technologies NASDAQ:AQB

Liminatus Pharma NASDAQ:LIMN

XTL Biopharmaceuticals NASDAQ:XTLB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABP, XTLB, AQB, and LIMN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABP, XTLB, AQB, and LIMN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABP, XTLB, AQB, and LIMN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABP, XTLB, AQB, and LIMN Company Descriptions

Abpro NASDAQ:ABP

AquaBounty Technologies NASDAQ:AQB

Liminatus Pharma NASDAQ:LIMN

XTL Biopharmaceuticals NASDAQ:XTLB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools